The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases

A Boucharaba, C-M Serre, J Guglielmi, J-C Bordet, P Clézardin, and O Peyruchaud PNAS, Vo. 103; no 25, 9643-9648, June 20, 2006